PerkinElmer & Predictive Diagnostics find Alzheimer's biomarkers:
This article was originally published in Clinica
Executive Summary
PerkinElmer and Predictive Diagnostics, under a research collaboration, have discovered biomarkers in blood for Alzheimer's Disease. The companies analysed blood using PerkinElmer's BioXPRESSION biomarker platform and Predictive Diagnostic's BAMF technology to identify patterns of proteins and peptides that distinguished Alzheimer's disease patients from those without clinical signs of the condition. Predictive Diagnostics' parent company, Vacaville, California-based Large Scale Biology, noted, however, that the results still needed to be replicated in a separate study. The findings were presented on April 14, at the American Association of Clinical Chemistry's Oak Ridge conference in Baltimore, Maryland.